Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 1, 2009, Pages 223-234

  Montague, Terri ^a   Murphy, Barbara ^b  

^a BROWN UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Hemodialysis; Hyperlipidemia; Renal transplantation; Statin

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; CLOFIBRATE; COLESTYRAMINE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RAPAMYCIN; ROSUVASTATIN; SEVELAMER; SIMVASTATIN; TACROLIMUS; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTERY CALCIFICATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DYSLIPIDEMIA; EXERCISE; FLUSHING; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LOW FAT DIET; MORTALITY; MUSCLE DISEASE; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; GUIDELINES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RENAL DIALYSIS;

EID: 59649099215     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.11.004     Document Type: Review

References (78)

1. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. N Engl J Med 335 14 (1996) 1001-1009
3. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 20 (1995) 1301-1307
4. Kronenberg F., Kuen E., Ritz E., et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11 1 (2000) 105-115
5. Weintraub M., Burstein A., Rassin T., et al. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42 5 (1992) 1247-1252
6. Galle J., and Wanner C. Modification of lipoproteins in uremia: oxidation, glycation and carbamoylation. Miner Electrolyte Metab 25 4-6 (1999) 263-268
7. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 9374 (2003) 2024-2031
8. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 3 (2005) 238-248
9. Molitch M.E. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 1 5 (2006) 1090-1099
10. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32 Suppl 3 (1998) S142-S156
11. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41 Suppl 3 (2003) S1-S91
12. Weiner D.E., and Sarnak M.J. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 19 10 (2004) 1045-1052
13. Attman P.O., Samuelsson O., Johansson A.C., et al. Dialysis modalities and dyslipidemia. Kidney Int 84 (2003) S110-S112
14. Kwan B.C., Kronenberg F., Beddhu S., et al. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18 4 (2007) 1246-1261
15. Zioncheck T.F., Powell L.M., Rice G.C., et al. Interaction of recombinant apolipoprotein (a) and lipoprotein (a) with macrophages. J Clin Invest 87 3 (1991) 767-771
16. Maggi E., Bellazzi R., Falaschi F., et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?. Kidney Int 45 3 (1994) 876-883
17. Craig W.Y., Neveux L.M., Palomaki G.E., et al. Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 44 11 (1998) 2301-2306
18. Nogueira J., and Weir M. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. Clin J Am Soc Nephrol 2 4 (2007) 766-785
19. Kronenberg F., Neyer U., Lhotta K., et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10 5 (1999) 1027-1036
20. Kerschdorfer L., Konig P., Neyer U., et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 144 2 (1999) 381-391
21. Kronenberg F., Konig P., Lhotta K., et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 14 9 (1994) 1399-1404
22. Cressman M.D., Heyka R.J., Paganini E.P., et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86 2 (1992) 475-482
23. Longenecker J.C., Klag M.J., Marcovina S.M., et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 16 6 (2005) 1794-1802
24. Arnadottir M. Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase. Scand J Clin Lab Invest 57 1 (1997) 1-11
25. Arnadottir M., and Nilsson-Ehle P. Has parathyroid hormone any influence on lipid metabolism in chronic renal failure?. Nephrol Dial Transplant 10 12 (1995) 2381-2382
26. Nishizawa Y., Shoji T., Kawagishi T., et al. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 62 (1997) S90-S92
27. Assmann G., Schulte H., Funke H., et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19 Suppl M (1998) M8-M14
28. Farbakhsh K., and Kasiske B.L. Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am 89 3 (2005) 689-699
29. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 3 (1984) 365-374
30. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 64 Suppl 2 (2004) 43-60
31. Muntner P., He J., Astor B.C., et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16 2 (2005) 529-538
32. Cheung A.K., Sarnak M.J., Yan G., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58 1 (2000) 353-362
33. Hahn R., Oette K., Mondorf H., et al. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48 3 (1983) 279-288
34. Koch M., Kutkuhn B., Grabensee B., et al. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 12 12 (1997) 2603-2611
35. Stack A.G., and Bloembergen W.E. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 12 7 (2001) 1516-1523
36. Lowrie E.G., and Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 5 (1990) 458-482
37. Iseki K., Yamazato M., Tozawa M., et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61 5 (2002) 1887-1893
38. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291 4 (2004) 451-459
39. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 10 (1995) 621-627
40. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96 5 (1997) 1398-1402
41. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4 Suppl 7 (2004) 13-53
42. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 25 (2002) 3143-3421
43. Stephens N.G., Parsons A., Schofield P.M., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347 9004 (1996) 781
44. Yusuf S., Dagenais G., Pogue J., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 342 3 (2000) 154-160
45. Boaz M., Smetana S., Weinstein T., et al. Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): randomised placebo-controlled trial. Lancet 356 9237 (2000) 1213-1218
46. Khajehdehi P. Effect of vitamins on the lipid profile of patients on regular hemodialysis. Scand J Urol Nephrol 34 1 (2000) 62-66
47. Pekkanen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322 24 (1990) 1700-1707
48. Stamler J., Wentworth D., and Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 20 (1986) 2823-2828
49. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004) 1495-1504
50. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 20 (1998) 1615-1622
51. Harris K.P., Wheeler D.C., and Chong C.C. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 61 4 (2002) 1469-1474
52. Saltissi D., Morgan C., Rigby R.J., et al. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 39 2 (2002) 283-290
53. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 12 (2004) 1557-1560
54. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 19 (1998) 1349-1357
55. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 9364 (2003) 1149-1158
56. Seliger S.L., Weiss N.S., Gillen D.L., et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61 1 (2002) 297-304
57. Jardine A.G., Holdaas H., Fellstrom B., et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant 4 6 (2004) 988-995
58. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84 (2003) S207-S210
59. Fellstrom B., Holdaas H., Jardine A.G., et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 30 1 (2007) 314-322
60. Fellstrom B., Zannad F., Schmieder R., et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients-design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6 5 (2005) 9
61. Bilchick K.C., Henrikson C.A., Skojec D., et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 148 2 (2004) 200-210
62. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 3 (2004) 720-732
63. Stern R.H., Yang B.B., Horton M., et al. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 37 9 (1997) 816-819
64. Launay-Vacher V., Izzedine H., and Deray G. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 101 1 (2005) 9-17
65. Chang J.W., Yang W.S., Min W.K., et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39 6 (2002) 1213-1217
66. Bianchi S., Bigazzi R., Caiazza A., et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 3 (2003) 565-570
67. Tonelli M., Moye L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 2 (2003) 98-104
68. Tonelli M., Collins D., Robins S., et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66 3 (2004) 1123-1130
69. Lee M.S., Kim S.M., Kim S.B., et al. Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients. Perit Dial Int 19 3 (1999) 280-283
70. Lucatello A., Sturani A., Di Nardo A.M., et al. Safe use of gemfibrozil in uremic patients on continuous ambulatory peritoneal dialysis. Nephron 78 3 (1998) 338
71. Clouatre Y., Leblanc M., Ouimet D., et al. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant 14 4 (1999) 1047-1048
72. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 111 2 (1994) 161-174
73. Broeders N., Knoop C., Antoine M., et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant 15 12 (2000) 1993-1999
74. Kamionna V.S., and Kashyap M.L. Mechanism of action of niacin. Am J Cardiol 101 8A (2008) 20B-26B
75. Nishizawa Y., Shoji T., Tabata T., et al. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl 71 (1999) S134-S136
76. Chertow G.M., Burke S.K., and Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 1 (2002) 245-252
77. Chertow G.M., Burke S.K., Dillon M.A., et al. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14 12 (1999) 2907-2914
78. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 5 (2005) 1815-1824